Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader...
Pharmaceutical
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T...
Tiziana to Advance TZLS-501 – Its Fully Human IL-6R Monoclonal Antibody
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active...
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually
CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...
ORYZON to Participate in Upcoming Events in September and October
MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural...
SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage...
Evaxion out-licenses vaccine candidate EVX-B3 to MSD
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway...
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed...
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage...
Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR")....
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
image1 VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the...
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of...
Fagron announces the acquisition of UCP in North America and FDA inspection update
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of...